TORONTO, Feb. 12 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT), a
developer, manufacturer and distributor of therapeutic medical laser systems,
today announced positive research and development results in the destruction
of individual cancer cell lines. This research is aimed at combining patented
photodynamic compounds (PDCs), under exclusive worldwide licence to Theralase,
with the Company's patented bio-feedback laser technology for the selective
destruction of cancers, bacteria, viruses and fat cells.
Theralase, in conjunction with University Health Network, Virginia Tech
and with financial support from the Ontario Centres of Excellence's Centre for
Photonics, commenced a project in July 2007 focused on assessing the
therapeutic potential of various PDCs in combination with the Company's
patented laser technology. The TLC-3000 project involves progressive
assessment of the destruction of cancerous cells in: individual cancer cell
lines, small animals, large animals and humans.
"Theralase is pleased to achieve the first milestone in our PDC project
aimed at combining the power of PDCs with our laser technology in the
destruction of cancerous cells," said Roger Dumoulin-White, President and CEO
of Theralase. "We expect to release the final results in a publication or
scientific symposium in the next few months."
Independent laboratory research has now confirmed significant efficacy of
all three PDCs, under assessment, in successfully killing brain cancer and
colon cancer cell lines. The PDCs employed in the trials have proven the
ability to selectively target cancerous cells over cells derived from healthy
tissue. Additional cancer cell lines and various bacterial species will be
evaluated in the next stage of the project to determine cell kill by the PDCs.
Theralase Technologies Inc. designs, manufactures and distributes
patented, super-pulsed laser technology used in a wide range of
bio-stimulation and bio-destruction clinical applications. The Theralase
technology platform targets several diverse healthcare sectors - firstly, for
non-invasive pain management and clinical therapy, in hundreds of neural
muscular skeletal conditions, including arthritis - secondly, to bio-stimulate
and accelerate wound care and healing, including; bone fracture regeneration
and osteoarthritic conditions - and thirdly, combining photodynamic compounds
with super-pulsed, biofeedback laser technology to attack specifically
targeted cancers, bacterium, viruses and fat cells. Visit the Theralase
website at www.theralase.com for more detailed information on the Company's
products and research.
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the contents of this
For further information:
For further information: Roger Dumoulin-White, Theralase Technologies
Inc., President & CEO, (416) 447-8455, email@example.com; Vanessa
Beresford, The Equicom Group Inc., (416) 815-0700, ext 227,